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Quinidine syncopeand factors associated with it are well
known among adult patients treated for cardiac ar-
rhythmias. To define factors that may influence the oc-
currence of syncope in children taking quinidine, the
clinical, anatomic, electrocardiographic, roentgeno-
graphic and pharmacologic data were compared in six
patients with syncope (Group A) and 22 patients without
syncope (Group B). There was a significant (chi-square
= 10.2, P = 0.001) relation between heart disease and
quinidine syncope: all six Group A (syncopal) patients
had heart disease whereas 15 of the 22 Group B (non-
syncopal) patients had no structural heart disease. In
contrast, no significant difference was noted between
Group A and Group B patients in mean age (11.4 versus
11.4 years), mean quinidine serum concentration (2.9
versus 2.3 Itg/ml), mean corrected QT interval before
quinidine (0.43 versus 0.40 second) or mean corrected
QT interval during quinidine therapy (0.46 versus 0.46
second) or between those taking digitalis and those not.
Two of the six Group A (syncopal)patients died dur-
ing therapy, one 6 days after initiating therapy and one
Syncope has been recognized as a complication of quinidine
administration since 1923 (I). Most previous reports in adults
(2-8) have related the syncope to quinidine-induced ven-
tricular tachycardia observed in cardiac patients who are
usually being treated for atrial flutter or fibrillation. Struc-
tural heart disease, hypokalemia and prolonged corrected
QT interval on the electrocardiogram (ECG) have been ob-
served to increase the vulnerability to ventricular arrhyth-
mias (9,10). However, there is no information on the oc-
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suddenly at home 6 months after beginning quinidine.
Another two of the six Group A patients exhibited hy-
pokalemia (both 2.9 mEq/liter) at the time of syncope,
2 weeks and 6 months, respectively, after initiation of
quinidinetherapy; bothsurvived.Syncope occurred within
8 days of initiation of quinidine therapy in three of the
six patients. Sustained ventricular tachycardia was ob-
served during quinidine associated arrhythmia in three
of six patients with syncope; nonsustained ventricular
tachycardia or complexventricular ectopicactivity while
on this therapy was observed before syncopein the other
three patients in Group A.
This experience indicates that quinidine-related syn-
cope in children is more likely to occur in patients with
structural heart disease, may be associated with hypo-
kalemia, is a result of ventricular tachycardia and may
be fatal. In the presence of heart disease, in-hospital
observation during the first 14 days and maintenance of
normokalemia is a prerequisite for quinidine therapy in
children.
(1 Am Coil Cardiol1987;9:1031-7)
currence of quinidine syncope in children. To examine for
factors among children that may predispose them to quin-
idine syncope we examined clinical, anatomic, ECG, roent-
genographic, hemodynamic and pharmacologic data in 28
children treated with quinidine at our institution. This report
summarizes that experience.
Methods
Study patients. To determine the number of children
treated with quinidine at our institution, the computer-as-
sisted patient data base of the Division of Pediatric Car-
diology, C. S. Mott Children's Hospital, University of
Michigan was interrogated for all patients with tachyar-
rhythmias. Three hundred fifty-five individuals seen during
the past IS years were detected; of these, 28 had been treated
with quinidine for more than 2 to 3 days. The records of
these 28 children were reviewed and then assigned to one
of two groups (Table I): Group A comprised 6 patients who
0735-1097/87/$3.50
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Pt. Age (yr) Anal. Treated QN-Related Syncope Before After Dose Level
No. &Sex Diagn. WithQN Arrhythmia (days) QN QN (rng/day) (tLg/ml )
Group A: Syncope
5.5M DORV, VEA VT 8 0.45 0.44 340 2.6
DCRV,
VSD
2 17.5F TA SIP, AFI NS-VT 6 0.40 0.48 800 2.5
Waterston
3 14.0M DTGA, SIP AFI NS-Vn 6 0.36 0.48 650 3.5
Mustard SSS
4 15.5F DTGA, SIP AFI VT 180 0.47 0.42 800 1.0
Mustard SSS
5 7.0M AVSD, SIP AFI VT 14 0.46 0.50 800 5.9
MVR
6 9.0F DTGA, SIP AFI NS-Vn 180 0.42 0.45 700 1.9
Mustard SSS
Group B: No Syncope
7 13.25F NSHD PSVT, WPW 0.45 0.47 800 2.5
8 15.3M NSHD PSVT, WPW 0.40 0.43 800 2.3
9 12.8M NSHD PSVT, WPW 0.38 0.40 800 2.6
10 18.5M NSHD PSVT, WPW 0.38 0.46 800 2.7
II 15.25F NSHD PSVT, WPW 0.38 0.43 1.200 2.6
12 17.75F NSHD PSVT. WPW 0.39 0.44 800 3.2
13 13.9M NSHD PSVT, WPW 0.39 0.44 800 1.4
14 5.25F NSHD PSVT, WPW 0.36 0.46 450 2.8
15 16.7F Ebstein's PSVT. WPW 0.44 0.46 650 1.9
anomaly
16 3.0F NSHD PSVT 0.37 0.45 400 1.6
17 4.5M Cardiomyopathy PSVT, WPW 0.46 0.44 400 1.6
18 12.7F DTGA, SIP AFI 0.39 0.49 \,000 3.3
Mustard SSS
19 12.IM NSHD PSVT, WPW 0.40 0.44 800 2.4
20 0.07M NSHD PSVT. WPW 0.35 0.47 360 1.1
21 6.9M DTGA, SIP AFI, 0.44 0.47 600 4.3
Mustard SSS,
VEA
22 2.IF NSHD PSVT 0,45 0.46 336 2.4
23 20.0M TOF. SIP VEA 0.44 0.52 1,000 1.6
repair
24 16.75M TOF, SIP PSVT, 0.44 0.47 1,200 1.1
repair VEA
25 15.2F NSHD PSVT, WPW 0.35 0.43 1,400 1.8
26 6.9F NSHD PSVT 0.40 0.44 400 1.3
27 15.0M VSD, SIP PSVT 0.55 800 2.6
repair,
PAH/PVOD
28 6.7M NSHD PSVT 0.39 0.42 800 3.8
*At syncope in Group A. tOn quinidine therapy in group B. :j:Recorded before death; §died 4 months after quinidine was discontinued; [died with
low cardiac output (see text). AFI = atrial flutter; Anal. Diagn. = anatomic diagnosis; Arrhy. = arrhythmia; AVSD = atrioventricular septal defect;
CTR = cardiothoracic ratio; DCRV = double chambered right ventricle; DORV == double outlet right ventricle; dTGA = dextro-transposition of the
great arteries; F = female; [K+] = serum potassium concentration; M = male; Mustard = Mustard repair of dTGA; MVR = mitral valve replacement;
lACC Vol. 9. NO. 5
May 1987:103 1-7
WEBB ET AL.
QUINIDINE SYNCOPE IN CHILDREN
1033
Table l. (continued)
Digitalis Minimal Heart Rates on
Serum Serum
Holter Tracings (beats/min)
PI. Dose Level IK 'I Before After Follow-Up
No. (/Lg/day) (ng/ml) (mliq/Iiter)" QN QN eTR Other Statust
Group A: Syncope
Digoxin. 1.5 4.9 58 79 n.56 Alive
120
2 Digitoxin, 2 1.4 4.3 67 !On 0.63 Alive
45
3 Digoxin. 3.8 9 1(AFI) 50 0.5 3 Dead
125
4 Digitoxin. 4.5 2.9 59 59 n.67 Pacemaker Alive
75
5 None 2.9 60 0.54 Alive
6 Digoxin, 1.4 4.n 60 60 0.63 Pacemaker Dead
62.5
Group B: No Syncope
7 6 1 0.40 Alive
8 54 60 0.40 Propranolol Alive
9 4 .3 46 61 0.38 Alive
10 61 0.40 Alive
II 85 58 n.44 Alive
12 3.6 7n 76 0.44 Alive
13 4.3 70 0.37 Alive
14 Digoxin, 1.5 73 0.52 Alive
125
15 76 n.49 Alive
16 47 75 Alive
17 Digoxin, 1.5 52 0.54 Alive
70
18 Digoxin, 13 4.4 76 60 0.47 Alive
12S
19 87 0.47 Alive
20 Digoxin, 1.8 71 96 0.58 Alive
70
2\ Digoxin, 1.2 98 73 0.59 Pacemaker Alive
120
22 Digoxin, 0.9 134(SVT) 152(SVT) 0.5 1 Propranolol Alive
180
23 Digoxin. 0.9 0.68 Pacemaker Al i ve ~
250
24 0.49 Propranolol. Alive
Dilantin
25 S5 56 Alive
26 Digoxin. 0.9 0.45 Alive
250
27 Digoxin. 2. 1 5S 0.76 Alive]
250
28 Digoxin 1.8 88 61 Propranolol Alive
187.5
NSHD = no structural heart disease; NS-VT = nonsustained ventricular tachycardia; PAH = pulmonary artery hypertension; PSVT = paroxysmal
supraventricular tachycardia; Pts. = no. of patients; PVOD = pulmonary vascular obstructive disease; QN = quinidine; QTc '" corrected QT interval;
SIP = status post; SSS = sick sinus syndrome; SVT = supraventricular tachycardia; TA '" tricuspid atresia; TOF '" tetralogy of Fallot: VEA =
ventricular ectopic activity; VSD '" ventricular septal defect; VT = ventricular tachycardia; WPW = Wolff-Parkinson-White syndrome. Normal digoxin
concentration is 9 to 25 ng/ml.
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experienced syncope while taking quinidine; Group B com-
prised 22 patients who were free of syncopebut treated with
quinidine. Patients who received quinidine for 2 to 3 days
but did not tolerate it because of nonarrhythmic-related side
effects, such as gastrointestinal symptoms, were excluded
from this study.
Patient data. The following data for all children were
recorded: follow-up status while taking quinidine (dead or
alive), age at time of quinidine administration, sex, ana-
tomic diagnosis, arrhythmia treated with quinidine, interval
from institution of quinidine to the onset of syncope and
the type of quinidine-related arrhythmia at the time of syn-
cope (when known). In all patients, ECGs were analyzed
before and after institution of quinidine for corrected QT
interval. In those patients with syncope the ECG obtained
most recently before the syncopal event was used; if avail-
able, the corrected QT interval at syncope was measured.
The quinidinedose, serumquinidine level, thedigitalisdose
and serum digitalis level and the serum potassium level (if
available) were also tabulated. Holter monitor tracings ob-
tained while the patient was receiving quinidine were ex-
amined for minimal heart rates. If syncope occurred, the
Holter tracing immediately preceding syncope was used.
Chest X-ray films taken at the time of initiationof quinidine
therapy were examined and the cardiothoracic ratio was
computed. Hemodynamic data, available in all patientswith
syncope and in II of 22 patients who did not have syncope,
were also reviewed.
Statistics. These clinical, electrocardiographic, radio-
logic, physiologic and pharmacologic characteristics were
compared between the two groups using a paired t test,
Fisher's exact test (two-tailed) and multiple discriminative
analysis and, where appropriate, expressed as mean ± SO;
probability (p) values <0.05 were considered significant.
Results
Syncope occurred in 21 % of the 28 children in our study
taking quinidine for treatment of arrhythmias. There was
no significant difference in either age at initiation of quin-
idine therapy or sex between the syncopal (Group A) and
nonsyncopal (Group B) groups. In Group A, five patients
had atrial flutter, three in association with sick sinus syn-
drome (II) and one patient had high grade ventricular ec-
topic activity; in Group B: 19 children had paroxysmal
supraventricular tachycardia and two had atrial flutter as-
sociated with sick sinus syndrome. The patients were fol-
lowed up for 4 months to 15 years (mean 3.2 years) after
the initiation of quinidine therapy.
Structural heart disease. The presence of heart disease
was strongly associated with syncope. In Group A three
patients had transposition of the great arteries after Mustard
repair and one patient each had double outlet right ventricle
after repair, tricuspid atresia after a Waterston shunt and
atrioventricular (AV) septal defect after repair and mitral
valve replacement. In Group B, 15 of 22 patients had no
structural heart disease, 2 had transposition of the great
arteries after Mustard repair, 2 had tetralogy of Fallot after
repair, I had cardiomyopathy, I had Ebstein's anomaly
(mild) of the tricuspid valve and I had a ventricular septal
defect after repair with associated pulmonary artery hyper-
tension and pulmonary vascularobstructivedisease. Patient
23 died suddenly4 monthsafter quinidinewasdiscontinued;
patient 27 died while taking quinidine with irreversible low
cardiac output not associated with arrhythmia (in an inten-
sive care unit with continuous hemodynamic and rhythm
monitoring). These two patients were classified in Group B
(nonsyncope). In short, all 6 patients with syncope had
structural heart disease but only 7 of 22 without syncope
had heart disease (chi-square == 10.2, P == 0.001).
Role of atrial flutter and fibrillation. All 6 patients
with syncopehad structural heart disease and 5 of the 6 had
atrial flutter as well; in contrast, only 7 of the 22 patients
without syncope had heart disease and only 2 of these had
atrial flutter. Becauseof the well knownassociationbetween
atrial flutter (or fibrillation), structural heart disease and
syncope/sudden death (12), the possibilitythat the observed
syncope in our patients was associated with atrial flutter
itself rather than with quinidine must be considered. To
address this issue, the patient data base was examined for
all patients with atrial flutter or fibrillation and structural
Figure l. Patient I. Sustained ven-
tricular tachycardia demonstrated by
Holter monitor. The patient was suc-
cessfully resuscitated.
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heart disease. Individuals with paroxysmal atrial flutter or
fibrillation (with or without the Wolff-Parkinson-White syn-
drome) but with a normal structural heart were excluded.
The 7 patients (5 syncopal patients and 2 nonsyncopal pa-
tients from the present study) were joined with 36 other
patients who had both structural heart disease and atrial
flutter (n = 31) or atrial fibrillation (n = 5) but who had
not received quinidine. Two of the untreated patients died
with low cardiac output and three died suddenly. For pur-
poses of analysis, all five of these patients were classified
in the group with syncope/suddendeath. Chi-square analysis
of these 43 patients (7 treated with quinidine and 36 not
treated), all with atrial flutter or fibrillation as well as struc-
tural heart disease, demonstrated a strong association (Fish-
er's exact probability = 0.004) between quinidine use and
syncope/sudden death. Thus, even when atrial flutter or
fibrillation is held constant, a strong relation exists between
quinidine and syncope in young persons with structural heart
disease.
Quinidine-related arrhythmia. The quinidine-related
arrhythmia was demonstrated by ECG monitoring to be
sustained ventricular tachycardia in three Group A patients
(Fig. I). In two other Group A patients, ECG tracings iden-
tified nonsustained ventricular tachycardia before the syn-
copal event. These two patients (Patients 3 and 6), both
with transposition of the great arteries and sick sinus syn-
drome with recurrent atrial flutter, died. The Holter tracing
of Patient 3 demonstrated slowing of the heart rate (1.2
second pause) just before initiation of nonsustained ven-
tricular tachycardia 2 days before he died. Patient 6 had
been treated with quinidine, digoxin and a pacemaker for
sick sinus syndrome during the 6 months before her death.
Holter monitor tracings at the onset of quinidine therapy
showed frequent ventricular premature beats as compared
with prequinidine tracings. Before discharge from the hos-
pital couplets and triplets had resolved although Lown clas-
sification grade II ventricular ectopic activity remained, The
remaining four patients recovered and are well.
Serum potassium and duration of quinidine therapy.
Serum potassium levels were available in only 9 of the 28
patients. In two of the patients who experienced syncope,
the serum potassium level was less than 3 mEq/liter. Both
patients were also taking diuretics at the time of hypokalemia
and syncope.
The interval from initiation ofquinidine therapy to syn-
cope ranged from 6 days to 6 months. Two of the three
patients who experienced syncope at an interval > 10 days
from initiation of therapy (one 14 days and one 6 months)
had a serum potassium concentration of 2.9 mEq/liter. One
patient died 6 months after the initiation of quinidine ther-
apy. Her serum potassium level was 4.0 mEq/liter during
attempted resuscitation. The other three patients, two of
three with documented normokalernia, had syncope 6 to 8
days after initiation of quinidine therapy.
QT interval. Three of 6 Group A patients (Cases I, 4
and 5) and 7 of the 22 Group B patients (Cases 7, 15, 17,
21-24) had a corrected QT interval ~0.43 second before
quinidine therapy, The mean corrected QT interval in Group
A before quinidine therapy (0.43 second), although longer.
because of the uniform presence of heart disease in Group
A, was not significantlydifferent from that of Group B (0.40
second). In two patients in Group A (Patients I and 4) the
mean corrected QT interval shortened after initiation of
quinidine therapy. Patient I exhibited a minor decrease in
this interval; at syncope it was 0.55 second. Patient 4 was
a 15.5 year old girl whose corrected QT interval shortened
from 0.47 to 0.42 second after quinidine therapy. However,
her quinidine level was only 1.0 JLg/ml, and she was hy-
pokalemic at the time of syncope. All but one patient in
Group B showed an increase in corrected QT interval after
beginning quinidine. The mean corrected QT interval after
quinidine therapy in Group A (0.46 second) was not sig-
nificantly different from that in Group B (0.46 second).
Interestingly, this interval did increase significantly after
quinidine therapy in those patients without syncope in con-
trast to those with syncope, an unexpected observation that
is explained, at least in part, by the decreased corrected QT
interval of Patient 4 after therapy.
Quinidine and digitalis dosage. The mean quinidine
dosage was not significantly different between the two groups,
ranging from 20 to 35 mg/kg per day in Group A and from
20 to 65 mg/kg per day in Group B. Mean serum quinidine
levels also were not significantly different between Group
A (2.9 ± 1.7 JLg/ml) and Group B (2.3 ± 0.8 JLg/ml).
Five patients in Group A and 10 in Group B were taking
digitalis preparations as well as quinidine. Three of the five
patients in Group A took digoxin and the other two were
taking digitoxin, The digoxin dose ranged from 62.5 to 125
JLg/day in Group A and 70 to 250 JLg/day in Group B. The
digitoxin dose in the two Group A patients was 45 and 75
/Lg/day, respectively. All patients had their digitalis dose
reducedwhen quinidine was initiated. In Group A, digitoxin
levels in the two patients were not elevated. In the three
Group A patients taking digoxin, the serum level was ele-
vated in Patient 3 (3.8 ng/ml), who died. Mean serum dig-
oxin level in Group B was 1.4 ng/ml (10 patients). Impor-
tantly, there was no significant relation between digitalis
use and syncope when the data were controlled for the
presence of heart disease.
Hemodynamics. The minimal heart rate during quini-
dine therapy for Group A (61 ± 4 beats/min) was not
significantly different from that for Group B (68 ± 16
beats/min). In addition, the difference in mean cardiotho-
racic ratio between Group A (0.59 ± 0.6) and Group B
(0.49 ± 0.1) could be accounted for by the presence of
structural heart disease. Finally, there was no difference
between Group A and Group B with respect to systemic
ventricular end-diastolic pressure (9.5 ± 5 versus 11,6 ±
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4 mm Hg, respectively) and cardiac index (4.5 ± I versus
3.2 ± 0.8 liters/min per rrr', respectively).
Discussion
Our data are in accord with those obtained in adults
(9,10), and indicate that quinidine-related syncope in chil-
dren results from ventricular tachycardia and is not infre-
quent in patients with serious structural heart disease or
hypokalemia. In adults taking quinidine, the reported in-
cidence of syncope ranges from 0.8 to 8% (2,5,9). The
contrasting 21% incidence of quinidine syncope in our study
most likely resulted from patient selection (albeit as com-
plete as possible) as well as the small number of patients
receiving quinidine. None of our patients were treated solely
for isolated ventricular premature beats. Nonetheless, this
incidence underscores the need for careful monitoring of
children given quinidine, especially those with serious struc-
tural heart disease.
Role of digoxin and prolonged QT interval. Several
investigators (2,5-7,9) have also suggested an increased risk
for syncope with concurrent digoxin use or in the presence
of a prolonged QT interval. Concurrent use of digitalis among
our patients was not clearly associated with quinidine syn-
cope when the data were controlled for the presence of heart
disease. On the other hand, one Group A patient who died
(Case 3) had an elevated digoxin level at the time of autopsy
(3.8 ng/ml). We noted a prolonged corrected QT interval
before quinidine treatment in three (50%) of the six patients
with syncope, which approximates the 71% incidence in
one review (9). However, in our pediatric group, the mag-
nitude of the observed increase in the corrected QT interval
after quinidine therapy was not associated with syncope,
thus suggesting that the presence of heart disease is a stronger
predictor of syncope than is the change in corrected QT
interval.
Quinidine-related ventricular arrhythmias. Quinidine
syncope related to ventricular arrhythmias has been de-
scribed in adults (1-10). In one report (9) all 31 adult pa-
tients with quinidine syncope had organic heart disease such
as ischemic heart disease, rheumatic heart disease, hyper-
tensive heart disease, congestive cardiomyopathy, sick sinus
syndrome, mitral valve prolapse or atrial septal defect. In
these patients, quinidine was used for control of atrial fi-
brillation or atrial flutter, ventricular arrhythmias and par-
oxysmal supraventricular tachycardia. Ninety percent of these
patients were also taking digoxin and all had therapeutic
serum digoxin levels. Five patients had a serum potassium
level less than 3.5 mEq/liter at the time of syncope. The
majority (71%) of patients had a prolonged QT interval
before initiation of quinidine therapy and 91% had a pro-
longed corrected QT interval after beginning quinidine. The
study (9) concluded that quinidine syncope is most often
idiosyncratic, not dose related, and usually occurs within I
week of initiation of therapy. Our data in children support
these conclusions.
Recently Ruskin et al. (10) showed by programmed ven-
tricular extrastimulation that adult patients with quinidine
syncope have an increased susceptibility to ventricular fi-
brillation in the presence of quinidine. Thus quinidine may
inherently increase the risk for life-threatening ventricular
arrhythmia in those patients with heart disease, including
children, and in those with hypokalemia. Unfortunately, in
patients with quinidine-related arrhythmias, other type I
antiarrhythmic drugs as well as amiodaronehave also been
associated with complex ventricular arrhythmias (13).
Several investigators (14,15) reported that adult patients
with underlying bradycardia in combination with a pro-
longed QT interval may be most vulnerable to ventricular
tachyarrhythmias. In one of our patients (Case 3), nonsus-
tained ventricular tachycardia noted in the Holter tracing
was heralded by a long pause. Further, the corrected QT
interval, as expected, increased after quinidine therapy in
25 of our 28 patients. This combination of bradycardia and
a prolongation of the corrected QT interval may also place
pediatric patients at increased risk for complex ventricular
tachycardia.
Role of underlying heart disease and surgical proce-
dure. Children, after a corrective venous baffle operation
for transposition of the great arteries, are known to exhibit
increased age-related bradyarrhythmias as well as intermit-
tent tachyarrhythmias compared with normal children (16),
and thus may be especially vulnerable to quinidine-induced
syncope. Indeed three of our five patients with transposition
receiving quinidine for atrial flutter experienced syncope;
two of the three (Cases 3 and 6) died suddenly while re-
ceiving therapy. On the other hand, when the 28 patients
were stratified for no structural heart disease, transposition
of the great arteries or other forms of heart disease, there
was no significant difference in either minimal heart rate or
corrected QT interval, before or after quinidine, either within
each group or among the three groups. Despite our inability
to firmly link quinidine syncope to the bradyarrhythmia
associated with venous operations for transposition, most
likely owing to the small number of patients in our study,
we recommend great care in the use of quinidine in these
patients. Paradoxically, because syncope or sudden death
in patients on quinidine therapy may also be related to the
natural history of the underlying heart disease, pacemaker
implantation to prevent possible proarrhythmic effects of
bradycardia in the presence of quinidine may not be an
effective measure (Patients 4 and 6).
Quinidine safety in absence of heart disease. At the
same time, based on experience with our Group B patients
as well as the experience of other investigators, quinidine,
in the absence of heart disease, is safe, and when effective
for the prophylaxis of paroxysmal supraventricular tachy-
cardia and other arrhythmias it can be given to outpatients,
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provided that there is normokalemia, a normal corrected QT
interval, no atrial fibrillation, no second or third degree heart
block, no digitalis toxicity and no prior quinidine toxicity
(17). The patients should be followed up with periodic Hol-
ter monitoring and serum potassium levels. If digitalis is
used concurrently, the digitalis dose should be reduced by
approximately 50%.
Quinidine therapy in presence of heart disease. In a
child with serious structural heart disease, the risks of quin-
idine therapy must be carefully weighed against the risks
of no quinidine therapy. Our recommendations for the use
of quinidine in a child with structural heart disease are as
follows: the patient should be observed in the hospital for
approximately 2 weeks with continuous ECG monitoring
and serial measurements of both serum potassium level and
corrected QT interval. Appropriate adjustment of digitalis
dosage should be made. Pacemaker implantation for pre-
vention of bradycardia should be considered in selected
patients. During this period, if no exacerbation of an ar-
rhythmia is noted, if the underlying arrhythmia is controlled
and if the serum potassium level remains within the normal
range, the patient may be discharged. Careful monitoring
of serum potassium level and the underlying cardiac rhythm
is required throughout therapy. Although other type I anti-
arrhythmic medications are not necessarily free of this com-
plication, other medications such as long-acting procain-
amide may be considered.
We gratefully acknowledge the expert secretarial assistance of Colleen
Rauch and Sandra Suter.
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